-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Nurix (NRIX)
-
-
-
-
-
-
-
Nurix (NRIX) PT Raised to $35 at Piper Sandler
-
-
-
-
-
-
-
Morgan Stanley Upgrades Nurix (NRIX) to Overweight
-
-
-
-
-
-
-
Nurix (NRIX) PT Raised to $29 at RBC Capital
-
-
-
-
-
-
-
Nurix (NRIX) PT Lowered to $12 at Leerink Partners
-
-
-
-
-
-
-
Goldman Sachs Starts Nurix (NRIX) at Buy
-
-
-
-
-
-
-
Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
-
409,058 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

